Search

Your search keyword '"Parra-H, A"' showing total 462 results
Start Over Author "Parra-H, A"
462 results on '"Parra-H, A"'

1. Publisher Correction: First large-scale study reveals important losses of managed honey bee and stingless bee colonies in Latin America

Author

Requier, Fabrice, Leyton, Malena Sibaja, Morales, Carolina L., Garibaldi, Lucas A., Giacobino, Agostina, Porrini, Martin Pablo, Rosso-Londoño, Juan Manuel, Velarde, Rodrigo A., Aignasse, Andrea, Aldea-Sánchez, Patricia, Allasino, Mariana Laura, Arredondo, Daniela, Audisio, Carina, Cagnolo, Natalia Bulacio, Basualdo, Marina, Branchiccela, Belén, Calderón, Rafael A., Castelli, Loreley, Castilhos, Dayson, Escareño, Francisca Contreras, Correa-Benítez, Adriana, da Silva, Fabiana Oliveira, Garnica, Diego Silva, de Groot, Grecia, Delgado-Cañedo, Andres, Fernández-Marín, Hermógenes, Freitas, Breno M., Galindo-Cardona, Alberto, Garcia, Nancy, Garrido, Paula M., Giray, Tugrul, Gonçalves, Lionel Segui, Landi, Lucas, Malusá Gonçalves, Daniel, Martinez, Silvia Inés, Moja, Pablo Joaquín, Molineri, Ana, Müller, Pablo Fernando, Nogueira, Enrique, Pacini, Adriana, Palacio, María Alejandra, Parra, Guiomar Nates, Parra-H, Alejandro, Peres Gramacho, Kátia, Castro, Eleazar Pérez, Pires, Carmen Sílvia Soares, Reynaldi, Francisco J., Luis, Anais Rodríguez, Rossini, Carmen, Sánchez Armijos, Milton, Santos, Estela, Scannapieco, Alejandra, Spina, Yamandú Mendoza, Tapia González, José María, Vargas Fernández, Andrés Marcelo, Viana, Blandina Felipe, Vieli, Lorena, Yadró García, Carlos Ariel, and Antúnez, Karina

Published
2024
Full Text
View/download PDF

2. First large-scale study reveals important losses of managed honey bee and stingless bee colonies in Latin America

Author

Requier, Fabrice, Leyton, Malena Sibaja, Morales, Carolina L., Garibaldi, Lucas A., Giacobino, Agostina, Porrini, Martin Pablo, Rosso-Londoño, Juan Manuel, Velarde, Rodrigo A., Aignasse, Andrea, Aldea-Sánchez, Patricia, Allasino, Mariana Laura, Arredondo, Daniela, Audisio, Carina, Cagnolo, Natalia Bulacio, Basualdo, Marina, Branchiccela, Belén, Calderón, Rafael A., Castelli, Loreley, Castilhos, Dayson, Escareño, Francisca Contreras, Correa-Benítez, Adriana, da Silva, Fabiana Oliveira, Garnica, Diego Silva, de Groot, Grecia, Delgado-Cañedo, Andres, Fernández-Marín, Hermógenes, Freitas, Breno M., Galindo-Cardona, Alberto, Garcia, Nancy, Garrido, Paula M., Giray, Tugrul, Gonçalves, Lionel Segui, Landi, Lucas, Malusá Gonçalves, Daniel, Martinez, Silvia Inés, Moja, Pablo Joaquín, Molineri, Ana, Müller, Pablo Fernando, Nogueira, Enrique, Pacini, Adriana, Palacio, María Alejandra, Parra, Guiomar Nates, Parra-H, Alejandro, Peres Gramacho, Kátia, Castro, Eleazar Pérez, Pires, Carmen Sílvia Soares, Reynaldi, Francisco J., Luis, Anais Rodríguez, Rossini, Carmen, Sánchez Armijos, Milton, Santos, Estela, Scannapieco, Alejandra, Spina, Yamandú Mendoza, Tapia González, José María, Vargas Fernández, Andrés Marcelo, Viana, Blandina Felipe, Vieli, Lorena, Yadró García, Carlos Ariel, and Antúnez, Karina

Published
2024
Full Text
View/download PDF

3. First large-scale study reveals important losses of managed honey bee and stingless bee colonies in Latin America

Author

Fabrice Requier, Malena Sibaja Leyton, Carolina L. Morales, Lucas A. Garibaldi, Agostina Giacobino, Martin Pablo Porrini, Juan Manuel Rosso-Londoño, Rodrigo A. Velarde, Andrea Aignasse, Patricia Aldea-Sánchez, Mariana Laura Allasino, Daniela Arredondo, Carina Audisio, Natalia Bulacio Cagnolo, Marina Basualdo, Belén Branchiccela, Rafael A. Calderón, Loreley Castelli, Dayson Castilhos, Francisca Contreras Escareño, Adriana Correa-Benítez, Fabiana Oliveira da Silva, Diego Silva Garnica, Grecia de Groot, Andres Delgado-Cañedo, Hermógenes Fernández-Marín, Breno M. Freitas, Alberto Galindo-Cardona, Nancy Garcia, Paula M. Garrido, Tugrul Giray, Lionel Segui Gonçalves, Lucas Landi, Daniel Malusá Gonçalves, Silvia Inés Martinez, Pablo Joaquín Moja, Ana Molineri, Pablo Fernando Müller, Enrique Nogueira, Adriana Pacini, María Alejandra Palacio, Guiomar Nates Parra, Alejandro Parra-H, Kátia Peres Gramacho, Eleazar Pérez Castro, Carmen Sílvia Soares Pires, Francisco J. Reynaldi, Anais Rodríguez Luis, Carmen Rossini, Milton Sánchez Armijos, Estela Santos, Alejandra Scannapieco, Yamandú Mendoza Spina, José María Tapia González, Andrés Marcelo Vargas Fernández, Blandina Felipe Viana, Lorena Vieli, Carlos Ariel Yadró García, and Karina Antúnez

Subjects
Beekeeping, Colony loss, Meliponiculture, Monitoring program, Pollinators, South America, Medicine, Science
Abstract

Abstract Over the last quarter century, increasing honey bee colony losses motivated standardized large-scale surveys of managed honey bees (Apis mellifera), particularly in Europe and the United States. Here we present the first large-scale standardized survey of colony losses of managed honey bees and stingless bees across Latin America. Overall, 1736 beekeepers and 165 meliponiculturists participated in the 2-year survey (2016–2017 and 2017–2018). On average, 30.4% of honey bee colonies and 39.6% of stingless bee colonies were lost per year across the region. Summer losses were higher than winter losses in stingless bees (30.9% and 22.2%, respectively) but not in honey bees (18.8% and 20.6%, respectively). Colony loss increased with operation size during the summer in both honey bees and stingless bees and decreased with operation size during the winter in stingless bees. Furthermore, losses differed significantly between countries and across years for both beekeepers and meliponiculturists. Overall, winter losses of honey bee colonies in Latin America (20.6%) position this region between Europe (12.5%) and the United States (40.4%). These results highlight the magnitude of bee colony losses occurring in the region and suggest difficulties in maintaining overall colony health and economic survival for beekeepers and meliponiculturists.

Published
2024
Full Text
View/download PDF

4. Publisher Correction: First large-scale study reveals important losses of managed honey bee and stingless bee colonies in Latin America

Author

Fabrice Requier, Malena Sibaja Leyton, Carolina L. Morales, Lucas A. Garibaldi, Agostina Giacobino, Martin Pablo Porrini, Juan Manuel Rosso-Londoño, Rodrigo A. Velarde, Andrea Aignasse, Patricia Aldea-Sánchez, Mariana Laura Allasino, Daniela Arredondo, Carina Audisio, Natalia Bulacio Cagnolo, Marina Basualdo, Belén Branchiccela, Rafael A. Calderón, Loreley Castelli, Dayson Castilhos, Francisca Contreras Escareño, Adriana Correa-Benítez, Fabiana Oliveira da Silva, Diego Silva Garnica, Grecia de Groot, Andres Delgado-Cañedo, Hermógenes Fernández-Marín, Breno M. Freitas, Alberto Galindo-Cardona, Nancy Garcia, Paula M. Garrido, Tugrul Giray, Lionel Segui Gonçalves, Lucas Landi, Daniel Malusá Gonçalves, Silvia Inés Martinez, Pablo Joaquín Moja, Ana Molineri, Pablo Fernando Müller, Enrique Nogueira, Adriana Pacini, María Alejandra Palacio, Guiomar Nates Parra, Alejandro Parra-H, Kátia Peres Gramacho, Eleazar Pérez Castro, Carmen Sílvia Soares Pires, Francisco J. Reynaldi, Anais Rodríguez Luis, Carmen Rossini, Milton Sánchez Armijos, Estela Santos, Alejandra Scannapieco, Yamandú Mendoza Spina, José María Tapia González, Andrés Marcelo Vargas Fernández, Blandina Felipe Viana, Lorena Vieli, Carlos Ariel Yadró García, and Karina Antúnez

Subjects
Medicine, Science
Published
2024
Full Text
View/download PDF

9. EUGLOSSINI BEES (HYMENOPTERA: APIDAE) IN SANTA RITA, PANAMA

Author

Janitce A. Harwood, Yostin J. Añino, and Alejando Parra-H

Subjects
Abundance, Colón, conservation, fragmented ecosystems, euglossines, Mathematics, QA1-939, Physics, QC1-999
Abstract

Santa Rita is a town located in the province of Colón, Panama. This area is threatened by various human activities that not only threaten the landscape and its vegetation, but also the integrity of the pollinators that live there. Considering this, we collected samples of bees from the Euglossini tribe in a fragmented area of Santa Rita, to get an idea of the population status in which these bees could be found at the site. Sampling was carried out one day during the dry season and one day in the rainy season of 2017. We collected 179 males belonging to 20 species, belonging to the three genera Euglossa (14 spp.), Eufriesea (4 spp.), and Eulaema (3 spp.). We know that these results are not enough to determine if Euglossini bee populations are stable or have decreased, but they give us a basis on the abundance and richness of the recorded species.

Published
2023

10. Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: practical indications from an Italian multidisciplinary group

Author

Malapelle, U, Donne, A, Pagni, F, Fraggetta, F, Rocco, E, Pasello, G, Perrone, G, Pepe, F, Vatrano, S, Pignata, S, Pinto, C, Pruneri, G, Russo, A, Soto Parra, H, Vallone, S, Marchetti, A, Troncone, G, Novello, S, Malapelle, Umberto, Donne, Alessandro Delle, Pagni, Fabio, Fraggetta, Filippo, Rocco, Elena Guerini, Pasello, Giulia, Perrone, Giuseppe, Pepe, Francesco, Vatrano, Simona, Pignata, Sandro, Pinto, Carmine, Pruneri, Giancarlo, Russo, Antonio, Soto Parra, Hector J, Vallone, Stefania, Marchetti, Antonio, Troncone, Giancarlo, Novello, Silvia, Malapelle, U, Donne, A, Pagni, F, Fraggetta, F, Rocco, E, Pasello, G, Perrone, G, Pepe, F, Vatrano, S, Pignata, S, Pinto, C, Pruneri, G, Russo, A, Soto Parra, H, Vallone, S, Marchetti, A, Troncone, G, Novello, S, Malapelle, Umberto, Donne, Alessandro Delle, Pagni, Fabio, Fraggetta, Filippo, Rocco, Elena Guerini, Pasello, Giulia, Perrone, Giuseppe, Pepe, Francesco, Vatrano, Simona, Pignata, Sandro, Pinto, Carmine, Pruneri, Giancarlo, Russo, Antonio, Soto Parra, Hector J, Vallone, Stefania, Marchetti, Antonio, Troncone, Giancarlo, and Novello, Silvia

Abstract

Molecular biomarker testing is increasingly becoming standard of care for advanced non-small cell lung cancer (NSCLC). Tissue and liquid biopsy-based next-generation sequencing (NGS) is now highly recommended and has become an integral part of the routine management of advanced NSCLC patients. This highly sensitive approach can simultaneously and efficiently detect multiple biomarkers even in scant samples. However full optimization of NGS in clinical practice requires accurate reporting and interpretation of NGS findings. Indeed, as the number of NSCLC biomarkers continues to grow, clinical reporting of NGS data is becoming increasingly complex. In this scenario, achieving standardization, simplification, and improved readability of NGS reports is key to ensuring timely and appropriate treatment decisions. In an effort to address the complexity and lengthy reporting of NGS mutation results, an Italian group of 14 healthcare professionals involved in NSCLC management convened in 2023 to address the content, structure, and ease-of-use of NGS reporting practices and proposed a standard report template for clinical use This article presents the key discussion points addressed by the Italian working group and describes the essential elements of the report template.

Published
2024

11. Predicting bee community responses to land-use changes: Effects of geographic and taxonomic biases.

Author

De Palma, Adriana, Abrahamczyk, Stefan, Aizen, Marcelo A, Albrecht, Matthias, Basset, Yves, Bates, Adam, Blake, Robin J, Boutin, Céline, Bugter, Rob, Connop, Stuart, Cruz-López, Leopoldo, Cunningham, Saul A, Darvill, Ben, Diekötter, Tim, Dorn, Silvia, Downing, Nicola, Entling, Martin H, Farwig, Nina, Felicioli, Antonio, Fonte, Steven J, Fowler, Robert, Franzén, Markus, Goulson, Dave, Grass, Ingo, Hanley, Mick E, Hendrix, Stephen D, Herrmann, Farina, Herzog, Felix, Holzschuh, Andrea, Jauker, Birgit, Kessler, Michael, Knight, ME, Kruess, Andreas, Lavelle, Patrick, Le Féon, Violette, Lentini, Pia, Malone, Louise A, Marshall, Jon, Pachón, Eliana Martínez, McFrederick, Quinn S, Morales, Carolina L, Mudri-Stojnic, Sonja, Nates-Parra, Guiomar, Nilsson, Sven G, Öckinger, Erik, Osgathorpe, Lynne, Parra-H, Alejandro, Peres, Carlos A, Persson, Anna S, Petanidou, Theodora, Poveda, Katja, Power, Eileen F, Quaranta, Marino, Quintero, Carolina, Rader, Romina, Richards, Miriam H, Roulston, T'ai, Rousseau, Laurent, Sadler, Jonathan P, Samnegård, Ulrika, Schellhorn, Nancy A, Schüepp, Christof, Schweiger, Oliver, Smith-Pardo, Allan H, Steffan-Dewenter, Ingolf, Stout, Jane C, Tonietto, Rebecca K, Tscharntke, Teja, Tylianakis, Jason M, Verboven, Hans AF, Vergara, Carlos H, Verhulst, Jort, Westphal, Catrin, Yoon, Hyung Joo, and Purvis, Andy

Subjects
Animals, Bees, Conservation of Natural Resources, Geography
Abstract

Land-use change and intensification threaten bee populations worldwide, imperilling pollination services. Global models are needed to better characterise, project, and mitigate bees' responses to these human impacts. The available data are, however, geographically and taxonomically unrepresentative; most data are from North America and Western Europe, overrepresenting bumblebees and raising concerns that model results may not be generalizable to other regions and taxa. To assess whether the geographic and taxonomic biases of data could undermine effectiveness of models for conservation policy, we have collated from the published literature a global dataset of bee diversity at sites facing land-use change and intensification, and assess whether bee responses to these pressures vary across 11 regions (Western, Northern, Eastern and Southern Europe; North, Central and South America; Australia and New Zealand; South East Asia; Middle and Southern Africa) and between bumblebees and other bees. Our analyses highlight strong regionally-based responses of total abundance, species richness and Simpson's diversity to land use, caused by variation in the sensitivity of species and potentially in the nature of threats. These results suggest that global extrapolation of models based on geographically and taxonomically restricted data may underestimate the true uncertainty, increasing the risk of ecological surprises.

Published
2016

12. First large-scale study reveals important losses of honey bee and stingless bee colonies in Latin America

Author

Requier, Fabrice, primary, Leyton, Malena Sibaja, additional, Morales, Carolina L., additional, Garibaldi, Lucas A., additional, Giacobino, Agostina, additional, Porrini, Martin P., additional, Rosso-Londoño, Juan Manuel, additional, Velarde, Rodrigo A., additional, Aignasse, Andrea, additional, Aldea-Sánchez, Patricia, additional, Allasino, Mariana Laura, additional, Arredondo, Daniela, additional, Audisio, Carina, additional, Cagnolo, Natalia Bulacio, additional, Basualdo, Marina, additional, Branchiccela, Belén, additional, Calderón, Rafael A., additional, Castelli, Loreley, additional, Castilhos, Dayson, additional, Escareño, Francisca Contreras, additional, Correa-Benítez, Adriana, additional, Silva, Fabiana Oliveira da, additional, Garnica, Diego Silva, additional, de Groot, Grecia, additional, Delgado-Cañedo, Andres, additional, Fernández-Marín, Hermógenes, additional, Freitas, Breno M., additional, Cardona, Alberto Galindo, additional, Garcia, Nancy, additional, Garrido, Paula M., additional, Giray, Tugrul, additional, Gonçalves, Lionel Segui, additional, Landi, Lucas, additional, Gonçalves, Daniel Malusá, additional, Martinez, Silvia, additional, Moja, Pablo Joaquín, additional, Molineri, Ana, additional, Müller, Pablo Fernando, additional, Nogueira, Enrique, additional, Pacini, Adriana, additional, Palacio, María Alejandra, additional, Parra, Guiomar Nates, additional, Parra-H, Alejandro, additional, Gramacho, Kátia Peres, additional, Pérez, Eleazar, additional, Pires, Carmen Sílvia Soares, additional, Reynaldi, Francisco J., additional, Luis, Anais Rodríguez, additional, Rossini, Carmen, additional, Armijos, Milton Sánchez, additional, Santos, Estela, additional, Scannapieco, Alejandra, additional, Spina, Yamandú Mendoza, additional, González, José María Tapia, additional, Fernández, Andrés Marcelo Vargas, additional, García, Carlos Ariel Yadró, additional, Viana, Blandina Felipe, additional, Vieli, Lorena, additional, and Antúnez, Karina, additional

Published
2023
Full Text
View/download PDF

13. SAFER: A Context-Aware Ubiquitous Assistance Platform for Elderly Care

Author

Bravo-Torres, J. F., Redrován-Parra, H. S., Soto-Sarango, A. F., Andrade-Padilla, J. A., Ordoñez-Morales, E. F., López-Nores, M., Blanco-Fernández, Y., Magjarevic, Ratko, Editor-in-Chief, Ładyżyński, Piotr, Series Editor, Ibrahim, Fatimah, Series Editor, Lacković, Igor, Series Editor, Rock, Emilio Sacristan, Series Editor, Torres, Isnardo, editor, Bustamante, John, editor, and Sierra, Daniel A., editor

Published
2017
Full Text
View/download PDF

14. Modelling and projecting the response of local assemblage composition to land use change across Colombia

Author

Echeverría-Londoño, Susy, Newbold, Tim, Hudson, Lawrence N., Contu, Sara, Hill, Samantha L. L., Lysenko, Igor, Arbeláez-Cortés, Enrique, Armbrecht, Inge, Boekhout, Teun, Cabra-García, Jimmy, Dominguez-Haydar, Yamileth, Nates-Parra, Guiomar, Gutiérrez-Lamus, Doris L., Higuera, Diego, Isaacs-Cubides, Paola Johanna, López-Quintero, Carlos A., Martinez, Eliana, Miranda-Esquivel, Daniel Rafael, Navarro-Iriarte, Luis Eduardo, Noriega, Jorge Ari, Otavo, Samuel Eduardo, Parra-H, Alejandro, Poveda, Katja, Ramirez-Pinilla, Martha P., Rey-Velasco, Juan Carlos, Rosselli, Loreta, Smith-Pardo, Allan H., Urbina-Cardona, José Nicolás, and Purvis, Andy

Published
2016

15. Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients

Author

Malapelle, U, Pilotto, S, Reale, M, Passiglia, F, Pisapia, P, Pepe, F, Belluomini, L, Galetta, D, Cortinovis, D, Tiseo, M, Passaro, A, Seminati, D, Pagni, F, Parra, H, Migliorino, M, Rocco, D, Troncone, G, Novello, S, Malapelle U., Pilotto S., Reale M. L., Passiglia F., Pisapia P., Pepe F., Belluomini L., Galetta D., Cortinovis D., Tiseo M., Passaro A., Seminati D., Pagni F., Parra H. S., Migliorino M. R., Rocco D., Troncone G., Novello S., Malapelle, U, Pilotto, S, Reale, M, Passiglia, F, Pisapia, P, Pepe, F, Belluomini, L, Galetta, D, Cortinovis, D, Tiseo, M, Passaro, A, Seminati, D, Pagni, F, Parra, H, Migliorino, M, Rocco, D, Troncone, G, Novello, S, Malapelle U., Pilotto S., Reale M. L., Passiglia F., Pisapia P., Pepe F., Belluomini L., Galetta D., Cortinovis D., Tiseo M., Passaro A., Seminati D., Pagni F., Parra H. S., Migliorino M. R., Rocco D., Troncone G., and Novello S.

Abstract

Epidermal growth factor receptor (EGFR) exon 20 insertions occur rarely among different cancer types, with the highest frequency reported among non-small-cell lung cancer (NSCLC) patients, particularly adenocarcinomas (ADCs). Exon 20 insertions fall back in the tyrosine kinase domain, and can be clustered into two principal groups represented by in frame insertions and three to 21 bp (corresponding to 1–7 amino acids) duplications within amino acids 762 and 774. The identification of these alterations is key for an adequate management of NSCLC patients due to the possibility to treat these patients with specific targeted therapies. Next generation sequencing (NGS) technology, able to detect several hotspot gene mutations for different patients simultaneously, is the best detection approach due to its higher sensitivity and specificity compared to other techniques. Here we reviewed the principal biological characteristics, the main detection technologies and treatment options for NSCLC patients harbouring EGFR exon 20 insertions.

Published
2022

16. The database of the PREDICTS (Projecting Responses of Ecological Diversity In Changing Terrestrial Systems) project

Author

Lawrence N. Hudson, Tim Newbold, Sara Contu, Samantha L. L. Hill, Igor Lysenko, Adriana De Palma, Helen R. P. Phillips, Tamera I. Alhusseini, Felicity E. Bedford, Dominic J. Bennett, Hollie Booth, Victoria J. Burton, Charlotte W. T. Chng, Argyrios Choimes, David L. P. Correia, Julie Day, Susy Echeverría‐Londoño, Susan R. Emerson, Di Gao, Morgan Garon, Michelle L. K. Harrison, Daniel J. Ingram, Martin Jung, Victoria Kemp, Lucinda Kirkpatrick, Callum D. Martin, Yuan Pan, Gwilym D. Pask‐Hale, Edwin L. Pynegar, Alexandra N. Robinson, Katia Sanchez‐Ortiz, Rebecca A. Senior, Benno I. Simmons, Hannah J. White, Hanbin Zhang, Job Aben, Stefan Abrahamczyk, Gilbert B. Adum, Virginia Aguilar‐Barquero, Marcelo A. Aizen, Belén Albertos, E. L. Alcala, Maria delMar Alguacil, Audrey Alignier, Marc Ancrenaz, Alan N. Andersen, Enrique Arbeláez‐Cortés, Inge Armbrecht, Víctor Arroyo‐Rodríguez, Tom Aumann, Jan C. Axmacher, Badrul Azhar, Adrián B. Azpiroz, Lander Baeten, Adama Bakayoko, András Báldi, John E. Banks, Sharad K. Baral, Jos Barlow, Barbara I. P. Barratt, Lurdes Barrico, Paola Bartolommei, Diane M. Barton, Yves Basset, Péter Batáry, Adam J. Bates, Bruno Baur, Erin M. Bayne, Pedro Beja, Suzan Benedick, Åke Berg, Henry Bernard, Nicholas J. Berry, Dinesh Bhatt, Jake E. Bicknell, Jochen H. Bihn, Robin J. Blake, Kadiri S. Bobo, Roberto Bóçon, Teun Boekhout, Katrin Böhning‐Gaese, Kevin J. Bonham, Paulo A. V. Borges, Sérgio H. Borges, Céline Boutin, Jérémy Bouyer, Cibele Bragagnolo, Jodi S. Brandt, Francis Q. Brearley, Isabel Brito, Vicenç Bros, Jörg Brunet, Grzegorz Buczkowski, Christopher M. Buddle, Rob Bugter, Erika Buscardo, Jörn Buse, Jimmy Cabra‐García, Nilton C. Cáceres, Nicolette L. Cagle, María Calviño‐Cancela, Sydney A. Cameron, Eliana M. Cancello, Rut Caparrós, Pedro Cardoso, Dan Carpenter, Tiago F. Carrijo, Anelena L. Carvalho, Camila R. Cassano, Helena Castro, Alejandro A. Castro‐Luna, Cerda B. Rolando, Alexis Cerezo, Kim Alan Chapman, Matthieu Chauvat, Morten Christensen, Francis M. Clarke, Daniel F.R. Cleary, Giorgio Colombo, Stuart P. Connop, Michael D. Craig, Leopoldo Cruz‐López, Saul A. Cunningham, Biagio D'Aniello, Neil D'Cruze, Pedro Giovâni daSilva, Martin Dallimer, Emmanuel Danquah, Ben Darvill, Jens Dauber, Adrian L. V. Davis, Jeff Dawson, Claudio deSassi, Benoit deThoisy, Olivier Deheuvels, Alain Dejean, Jean‐Louis Devineau, Tim Diekötter, Jignasu V. Dolia, Erwin Domínguez, Yamileth Dominguez‐Haydar, Silvia Dorn, Isabel Draper, Niels Dreber, Bertrand Dumont, Simon G. Dures, Mats Dynesius, Lars Edenius, Paul Eggleton, Felix Eigenbrod, Zoltán Elek, Martin H. Entling, Karen J. Esler, Ricardo F. deLima, Aisyah Faruk, Nina Farwig, Tom M. Fayle, Antonio Felicioli, Annika M. Felton, Roderick J. Fensham, Ignacio C. Fernandez, Catarina C. Ferreira, Gentile F. Ficetola, Cristina Fiera, Bruno K. C. Filgueiras, Hüseyin K. Fırıncıoğlu, David Flaspohler, Andreas Floren, Steven J. Fonte, Anne Fournier, Robert E. Fowler, Markus Franzén, Lauchlan H. Fraser, Gabriella M. Fredriksson, Geraldo B. Freire Jr, Tiago L. M. Frizzo, Daisuke Fukuda, Dario Furlani, René Gaigher, Jörg U. Ganzhorn, Karla P. García, Juan C. Garcia‐R, Jenni G. Garden, Ricardo Garilleti, Bao‐Ming Ge, Benoit Gendreau‐Berthiaume, Philippa J. Gerard, Carla Gheler‐Costa, Benjamin Gilbert, Paolo Giordani, Simonetta Giordano, Carly Golodets, Laurens G. L. Gomes, Rachelle K. Gould, Dave Goulson, Aaron D. Gove, Laurent Granjon, Ingo Grass, Claudia L. Gray, James Grogan, Weibin Gu, Moisès Guardiola, Nihara R. Gunawardene, Alvaro G. Gutierrez, Doris L. Gutiérrez‐Lamus, Daniela H. Haarmeyer, Mick E. Hanley, Thor Hanson, Nor R. Hashim, Shombe N. Hassan, Richard G. Hatfield, Joseph E. Hawes, Matt W. Hayward, Christian Hébert, Alvin J. Helden, John‐André Henden, Philipp Henschel, Lionel Hernández, James P. Herrera, Farina Herrmann, Felix Herzog, Diego Higuera‐Diaz, Branko Hilje, Hubert Höfer, Anke Hoffmann, Finbarr G. Horgan, Elisabeth Hornung, Roland Horváth, Kristoffer Hylander, Paola Isaacs‐Cubides, Hiroaki Ishida, Masahiro Ishitani, Carmen T. Jacobs, Víctor J. Jaramillo, Birgit Jauker, F. Jiménez Hernández, McKenzie F. Johnson, Virat Jolli, Mats Jonsell, S. Nur Juliani, Thomas S. Jung, Vena Kapoor, Heike Kappes, Vassiliki Kati, Eric Katovai, Klaus Kellner, Michael Kessler, Kathryn R. Kirby, Andrew M. Kittle, Mairi E. Knight, Eva Knop, Florian Kohler, Matti Koivula, Annette Kolb, Mouhamadou Kone, Ádám Kőrösi, Jochen Krauss, Ajith Kumar, Raman Kumar, David J. Kurz, Alex S. Kutt, Thibault Lachat, Victoria Lantschner, Francisco Lara, Jesse R. Lasky, Steven C. Latta, William F. Laurance, Patrick Lavelle, Violette Le Féon, Gretchen LeBuhn, Jean‐Philippe Légaré, Valérie Lehouck, María V. Lencinas, Pia E. Lentini, Susan G. Letcher, Qi Li, Simon A. Litchwark, Nick A. Littlewood, Yunhui Liu, Nancy Lo‐Man‐Hung, Carlos A. López‐Quintero, Mounir Louhaichi, Gabor L. Lövei, Manuel Esteban Lucas‐Borja, Victor H. Luja, Matthew S. Luskin, M Cristina MacSwiney G, Kaoru Maeto, Tibor Magura, Neil Aldrin Mallari, Louise A. Malone, Patrick K. Malonza, Jagoba Malumbres‐Olarte, Salvador Mandujano, Inger E. Måren, Erika Marin‐Spiotta, Charles J. Marsh, E. J. P. Marshall, Eliana Martínez, Guillermo Martínez Pastur, David Moreno Mateos, Margaret M. Mayfield, Vicente Mazimpaka, Jennifer L. McCarthy, Kyle P. McCarthy, Quinn S. McFrederick, Sean McNamara, Nagore G. Medina, Rafael Medina, Jose L. Mena, Estefania Mico, Grzegorz Mikusinski, Jeffrey C. Milder, James R. Miller, Daniel R. Miranda‐Esquivel, Melinda L. Moir, Carolina L. Morales, Mary N. Muchane, Muchai Muchane, Sonja Mudri‐Stojnic, A. Nur Munira, Antonio Muoñz‐Alonso, B. F. Munyekenye, Robin Naidoo, A. Naithani, Michiko Nakagawa, Akihiro Nakamura, Yoshihiro Nakashima, Shoji Naoe, Guiomar Nates‐Parra, Dario A. Navarrete Gutierrez, Luis Navarro‐Iriarte, Paul K. Ndang'ang'a, Eike L. Neuschulz, Jacqueline T. Ngai, Violaine Nicolas, Sven G. Nilsson, Norbertas Noreika, Olivia Norfolk, Jorge Ari Noriega, David A. Norton, Nicole M. Nöske, A. Justin Nowakowski, Catherine Numa, Niall O'Dea, Patrick J. O'Farrell, William Oduro, Sabine Oertli, Caleb Ofori‐Boateng, Christopher Omamoke Oke, Vicencio Oostra, Lynne M. Osgathorpe, Samuel Eduardo Otavo, Navendu V. Page, Juan Paritsis, Alejandro Parra‐H, Luke Parry, Guy Pe'er, Peter B. Pearman, Nicolás Pelegrin, Raphaël Pélissier, Carlos A. Peres, Pablo L. Peri, Anna S. Persson, Theodora Petanidou, Marcell K. Peters, Rohan S. Pethiyagoda, Ben Phalan, T. Keith Philips, Finn C. Pillsbury, Jimmy Pincheira‐Ulbrich, Eduardo Pineda, Joan Pino, Jaime Pizarro‐Araya, A. J. Plumptre, Santiago L. Poggio, Natalia Politi, Pere Pons, Katja Poveda, Eileen F. Power, Steven J. Presley, Vânia Proença, Marino Quaranta, Carolina Quintero, Romina Rader, B. R. Ramesh, Martha P. Ramirez‐Pinilla, Jai Ranganathan, Claus Rasmussen, Nicola A. Redpath‐Downing, J. Leighton Reid, Yana T. Reis, José M. Rey Benayas, Juan Carlos Rey‐Velasco, Chevonne Reynolds, Danilo Bandini Ribeiro, Miriam H. Richards, Barbara A. Richardson, Michael J. Richardson, Rodrigo Macip Ríos, Richard Robinson, Carolina A. Robles, Jörg Römbke, Luz Piedad Romero‐Duque, Matthias Rös, Loreta Rosselli, Stephen J. Rossiter, Dana S. Roth, T'ai H. Roulston, Laurent Rousseau, André V. Rubio, Jean‐Claude Ruel, Jonathan P. Sadler, Szabolcs Sáfián, Romeo A. Saldaña‐Vázquez, Katerina Sam, Ulrika Samnegård, Joana Santana, Xavier Santos, Jade Savage, Nancy A. Schellhorn, Menno Schilthuizen, Ute Schmiedel, Christine B. Schmitt, Nicole L. Schon, Christof Schüepp, Katharina Schumann, Oliver Schweiger, Dawn M. Scott, Kenneth A. Scott, Jodi L. Sedlock, Steven S. Seefeldt, Ghazala Shahabuddin, Graeme Shannon, Douglas Sheil, Frederick H. Sheldon, Eyal Shochat, Stefan J. Siebert, Fernando A. B. Silva, Javier A. Simonetti, Eleanor M. Slade, Jo Smith, Allan H. Smith‐Pardo, Navjot S. Sodhi, Eduardo J. Somarriba, Ramón A. Sosa, Grimaldo Soto Quiroga, Martin‐Hugues St‐Laurent, Brian M. Starzomski, Constanti Stefanescu, Ingolf Steffan‐Dewenter, Philip C. Stouffer, Jane C. Stout, Ayron M. Strauch, Matthew J. Struebig, Zhimin Su, Marcela Suarez‐Rubio, Shinji Sugiura, Keith S. Summerville, Yik‐Hei Sung, Hari Sutrisno, Jens‐Christian Svenning, Tiit Teder, Caragh G. Threlfall, Anu Tiitsaar, Jacqui H. Todd, Rebecca K. Tonietto, Ignasi Torre, Béla Tóthmérész, Teja Tscharntke, Edgar C. Turner, Jason M. Tylianakis, Marcio Uehara‐Prado, Nicolas Urbina‐Cardona, Denis Vallan, Adam J. Vanbergen, Heraldo L. Vasconcelos, Kiril Vassilev, Hans A. F. Verboven, Maria João Verdasca, José R. Verdú, Carlos H. Vergara, Pablo M. Vergara, Jort Verhulst, Massimiliano Virgilio, Lien Van Vu, Edward M. Waite, Tony R. Walker, Hua‐Feng Wang, Yanping Wang, James I. Watling, Britta Weller, Konstans Wells, Catrin Westphal, Edward D. Wiafe, Christopher D. Williams, Michael R. Willig, John C. Z. Woinarski, Jan H. D. Wolf, Volkmar Wolters, Ben A. Woodcock, Jihua Wu, Joseph M. Wunderle Jr, Yuichi Yamaura, Satoko Yoshikura, Douglas W. Yu, Andrey S. Zaitsev, Juliane Zeidler, Fasheng Zou, Ben Collen, Rob M. Ewers, Georgina M. Mace, Drew W. Purves, Jörn P. W. Scharlemann, and Andy Purvis

Subjects
data sharing, global biodiversity modeling, global change, habitat destruction, land use, Ecology, QH540-549.5
Abstract

Abstract The PREDICTS project—Projecting Responses of Ecological Diversity In Changing Terrestrial Systems (https://www.nhm.ac.uk/our-science/our-work/biodiversity/predicts.html)—has collated from published studies a large, reasonably representative database of comparable samples of biodiversity from multiple sites that differ in the nature or intensity of human impacts relating to land use. We have used this evidence base to develop global and regional statistical models of how local biodiversity responds to these measures. We describe and make freely available this 2016 release of the database, containing more than 3.2 million records sampled at over 26,000 locations and representing over 47,000 species. We outline how the database can help in answering a range of questions in ecology and conservation biology. To our knowledge, this is the largest and most geographically and taxonomically representative database of spatial comparisons of biodiversity that has been collated to date; it will be useful to researchers and international efforts wishing to model and understand the global status of biodiversity.

Published
2017
Full Text
View/download PDF

17. Are Orchid Bees (Apidae: Euglossini) Good Indicators of the State of Conservation of Neotropical Forests?

Author

Yostin Añino, Alejandro Parra-H, and Dumas Gálvez

Subjects
wild bees, bioindicator, neotropics, Zoology, QL1-991, Ecology, QH540-549.5, Natural history (General), QH1-278.5
Abstract

This work discusses the criteria proposed to consider wild bees as bioindicators and specifically applied to orchid bees in neotropical forests. Some of the issues are: 1) the deficiencies of the sampling methods, which makes it difficult to accurately assess species inventories. 2) missing knowledge about the biology of many species. 3) spatial or temporal distribution of most species remains unknown, which may misslead the results of short-term studies. 4) It is not clear whether orchid bees are affected by climate change as seen in other bees, which weakens their predictive potential. 5) A measure of the economic benefits provided by orchid bees is needed to better appraise them and their conservation. Finally, future studies should develop predictive models for conservation, accounting for evolutionary aspects like phylogeny or distributions; together with studies of the effect of disturbance on the physiology of the bees.

Published
2019
Full Text
View/download PDF

20. Interaction networks and the use of floral resources by male orchid bees (Hymenoptera: Apidae: Euglossini) in a primary rain forests of the Chocó Region (Colombia)

Author

Rodulfo Ospina-Torres, Paula María Montoya-Pfeiffer, Alejandro Parra-H., Víctor Solarte, and Joel Tupac Otero

Subjects
polinizadores, redes de interacciones, relación planta-insecto, Reserva Natural del Río Ñambí, Biology (General), QH301-705.5
Abstract

Orchid bees are important keystone pollinators from the Neotropics. With the aim to study the relationships between orchid bees and their nectar and aromatic host species, we made systematic samplings of males across two conservation areas in the biogeographic Chocó Region of Colombia. We used chemical baits to collect 352 male bees during five months. The pollen attached to their bodies was extracted for palynological identification and to estimate interaction networks. The euglossine community consisted of at least 22 species including Eg. maculilabris, Eg. orellana, Eg. championiand Eg. ignita.The male bees were associated with 84 plants but depended on a small group of them (Peperomiaspp. and Anthuriumspp, as well as species of Solanaceae, Ericaceae and Malpighiaceae) which were widely distributed across the altitudinal gradient, and were available through the year. The resulting interaction networks revealed a typical nested pattern usually found in plant-pollinator interactions, with several rare bee and plant species interaction with a small group of generalist bees and plant species. Albeit, we found variation within networks related to species composition. Such variation may be a consequence of specific differences in plant flowering phenology.

Published
2015

21. EP16.03-040 Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base

Author

Malapelle, U., primary, Pepe, F., additional, Pisapia, P., additional, Righi, L., additional, Listì, A., additional, Reale, M.L., additional, Passiglia, F., additional, Tiseo, M., additional, Genova, C., additional, Galetta, D., additional, Cortinovis, D., additional, Pilotto, S., additional, Migliorino, M.R., additional, Parra, H. Soto, additional, Cappuzzo, F., additional, Novello, S., additional, and Troncone, G., additional

Published
2022
Full Text
View/download PDF

22. EP02.04-001 Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)

Author

Leonetti, A., primary, Minari, R., additional, Boni, L., additional, Gnetti, L., additional, Bordi, P., additional, Verzè, M., additional, Ampollini, L., additional, Gelsomino, F., additional, Toschi, L., additional, Cecere, F., additional, Pilotto, S., additional, Metro, G., additional, Passiglia, F., additional, Cortinovis, D., additional, Guaitoli, G., additional, Pasello, G., additional, Delmonte, A., additional, Mazzoni, F., additional, Bria, E., additional, Galetta, D., additional, Genova, C., additional, Rocco, D., additional, Soto Parra, H., additional, Bearz, A., additional, Migliorino, M.R., additional, Camerini, A., additional, Tognetto, M., additional, and Tiseo, M., additional

Published
2022
Full Text
View/download PDF

23. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Mangano, S., Tonato, M., Zucca, E., Valsecchi, M.G., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., Dell'Oro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., and Otero, M.

Published
2014
Full Text
View/download PDF

24. The PREDICTS database: a global database of how local terrestrial biodiversity responds to human impacts

Author

Lawrence N. Hudson, Tim Newbold, Sara Contu, Samantha L. L. Hill, Igor Lysenko, Adriana De Palma, Helen R. P. Phillips, Rebecca A. Senior, Dominic J. Bennett, Hollie Booth, Argyrios Choimes, David L. P. Correia, Julie Day, Susy Echeverría‐Londoño, Morgan Garon, Michelle L. K. Harrison, Daniel J. Ingram, Martin Jung, Victoria Kemp, Lucinda Kirkpatrick, Callum D. Martin, Yuan Pan, Hannah J. White, Job Aben, Stefan Abrahamczyk, Gilbert B. Adum, Virginia Aguilar‐Barquero, Marcelo A. Aizen, Marc Ancrenaz, Enrique Arbeláez‐Cortés, Inge Armbrecht, Badrul Azhar, Adrián B. Azpiroz, Lander Baeten, András Báldi, John E. Banks, Jos Barlow, Péter Batáry, Adam J. Bates, Erin M. Bayne, Pedro Beja, Åke Berg, Nicholas J. Berry, Jake E. Bicknell, Jochen H. Bihn, Katrin Böhning‐Gaese, Teun Boekhout, Céline Boutin, Jérémy Bouyer, Francis Q. Brearley, Isabel Brito, Jörg Brunet, Grzegorz Buczkowski, Erika Buscardo, Jimmy Cabra‐García, María Calviño‐Cancela, Sydney A. Cameron, Eliana M. Cancello, Tiago F. Carrijo, Anelena L. Carvalho, Helena Castro, Alejandro A. Castro‐Luna, Rolando Cerda, Alexis Cerezo, Matthieu Chauvat, Frank M. Clarke, Daniel F. R. Cleary, Stuart P. Connop, Biagio D'Aniello, Pedro Giovâni daSilva, Ben Darvill, Jens Dauber, Alain Dejean, Tim Diekötter, Yamileth Dominguez‐Haydar, Carsten F. Dormann, Bertrand Dumont, Simon G. Dures, Mats Dynesius, Lars Edenius, Zoltán Elek, Martin H. Entling, Nina Farwig, Tom M. Fayle, Antonio Felicioli, Annika M. Felton, Gentile F. Ficetola, Bruno K. C. Filgueiras, Steven J. Fonte, Lauchlan H. Fraser, Daisuke Fukuda, Dario Furlani, Jörg U. Ganzhorn, Jenni G. Garden, Carla Gheler‐Costa, Paolo Giordani, Simonetta Giordano, Marco S. Gottschalk, Dave Goulson, Aaron D. Gove, James Grogan, Mick E. Hanley, Thor Hanson, Nor R. Hashim, Joseph E. Hawes, Christian Hébert, Alvin J. Helden, John‐André Henden, Lionel Hernández, Felix Herzog, Diego Higuera‐Diaz, Branko Hilje, Finbarr G. Horgan, Roland Horváth, Kristoffer Hylander, Paola Isaacs‐Cubides, Masahiro Ishitani, Carmen T. Jacobs, Víctor J. Jaramillo, Birgit Jauker, Mats Jonsell, Thomas S. Jung, Vena Kapoor, Vassiliki Kati, Eric Katovai, Michael Kessler, Eva Knop, Annette Kolb, Ádám Kőrösi, Thibault Lachat, Victoria Lantschner, Violette Le Féon, Gretchen LeBuhn, Jean‐Philippe Légaré, Susan G. Letcher, Nick A. Littlewood, Carlos A. López‐Quintero, Mounir Louhaichi, Gabor L. Lövei, Manuel Esteban Lucas‐Borja, Victor H. Luja, Kaoru Maeto, Tibor Magura, Neil Aldrin Mallari, Erika Marin‐Spiotta, E. J. P. Marshall, Eliana Martínez, Margaret M. Mayfield, Grzegorz Mikusinski, Jeffrey C. Milder, James R. Miller, Carolina L. Morales, Mary N. Muchane, Muchai Muchane, Robin Naidoo, Akihiro Nakamura, Shoji Naoe, Guiomar Nates‐Parra, Dario A. Navarrete Gutierrez, Eike L. Neuschulz, Norbertas Noreika, Olivia Norfolk, Jorge Ari Noriega, Nicole M. Nöske, Niall O'Dea, William Oduro, Caleb Ofori‐Boateng, Chris O. Oke, Lynne M. Osgathorpe, Juan Paritsis, Alejandro Parra‐H, Nicolás Pelegrin, Carlos A. Peres, Anna S. Persson, Theodora Petanidou, Ben Phalan, T. Keith Philips, Katja Poveda, Eileen F. Power, Steven J. Presley, Vânia Proença, Marino Quaranta, Carolina Quintero, Nicola A. Redpath‐Downing, J. Leighton Reid, Yana T. Reis, Danilo B. Ribeiro, Barbara A. Richardson, Michael J. Richardson, Carolina A. Robles, Jörg Römbke, Luz Piedad Romero‐Duque, Loreta Rosselli, Stephen J. Rossiter, T'ai H. Roulston, Laurent Rousseau, Jonathan P. Sadler, Szabolcs Sáfián, Romeo A. Saldaña‐Vázquez, Ulrika Samnegård, Christof Schüepp, Oliver Schweiger, Jodi L. Sedlock, Ghazala Shahabuddin, Douglas Sheil, Fernando A. B. Silva, Eleanor M. Slade, Allan H. Smith‐Pardo, Navjot S. Sodhi, Eduardo J. Somarriba, Ramón A. Sosa, Jane C. Stout, Matthew J. Struebig, Yik‐Hei Sung, Caragh G. Threlfall, Rebecca Tonietto, Béla Tóthmérész, Teja Tscharntke, Edgar C. Turner, Jason M. Tylianakis, Adam J. Vanbergen, Kiril Vassilev, Hans A. F. Verboven, Carlos H. Vergara, Pablo M. Vergara, Jort Verhulst, Tony R. Walker, Yanping Wang, James I. Watling, Konstans Wells, Christopher D. Williams, Michael R. Willig, John C. Z. Woinarski, Jan H. D. Wolf, Ben A. Woodcock, Douglas W. Yu, Andrey S. Zaitsev, Ben Collen, Rob M. Ewers, Georgina M. Mace, Drew W. Purves, Jörn P. W. Scharlemann, and Andy Purvis

Subjects
Data sharing, global change, habitat destruction, land use, Ecology, QH540-549.5
Abstract

Abstract Biodiversity continues to decline in the face of increasing anthropogenic pressures such as habitat destruction, exploitation, pollution and introduction of alien species. Existing global databases of species’ threat status or population time series are dominated by charismatic species. The collation of datasets with broad taxonomic and biogeographic extents, and that support computation of a range of biodiversity indicators, is necessary to enable better understanding of historical declines and to project – and avert – future declines. We describe and assess a new database of more than 1.6 million samples from 78 countries representing over 28,000 species, collated from existing spatial comparisons of local‐scale biodiversity exposed to different intensities and types of anthropogenic pressures, from terrestrial sites around the world. The database contains measurements taken in 208 (of 814) ecoregions, 13 (of 14) biomes, 25 (of 35) biodiversity hotspots and 16 (of 17) megadiverse countries. The database contains more than 1% of the total number of all species described, and more than 1% of the described species within many taxonomic groups – including flowering plants, gymnosperms, birds, mammals, reptiles, amphibians, beetles, lepidopterans and hymenopterans. The dataset, which is still being added to, is therefore already considerably larger and more representative than those used by previous quantitative models of biodiversity trends and responses. The database is being assembled as part of the PREDICTS project (Projecting Responses of Ecological Diversity In Changing Terrestrial Systems – https://www.nhm.ac.uk/our-science/our-work/biodiversity/predicts.html). We make site‐level summary data available alongside this article. The full database will be publicly available in 2015.

Published
2014
Full Text
View/download PDF

28. High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases

Author

Lagana, M, Gurizzan, C, Roca, E, Cortinovis, D, Signorelli, D, Pagani, F, Bettini, A, Bonomi, L, Rinaldi, S, Berardi, R, Filetti, M, Giusti, R, Pilotto, S, Milella, M, Intagliata, S, Baggi, A, Cortellini, A, Soto Parra, H, Brighenti, M, Petrelli, F, Bennati, C, Bidoli, P, Garassino, M, Berruti, A, Lagana M., Gurizzan C., Roca E., Cortinovis D., Signorelli D., Pagani F., Bettini A., Bonomi L., Rinaldi S., Berardi R., Filetti M., Giusti R., Pilotto S., Milella M., Intagliata S., Baggi A., Cortellini A., Soto Parra H., Brighenti M., Petrelli F., Bennati C., Bidoli P., Garassino M. C., Berruti A., Lagana, M, Gurizzan, C, Roca, E, Cortinovis, D, Signorelli, D, Pagani, F, Bettini, A, Bonomi, L, Rinaldi, S, Berardi, R, Filetti, M, Giusti, R, Pilotto, S, Milella, M, Intagliata, S, Baggi, A, Cortellini, A, Soto Parra, H, Brighenti, M, Petrelli, F, Bennati, C, Bidoli, P, Garassino, M, Berruti, A, Lagana M., Gurizzan C., Roca E., Cortinovis D., Signorelli D., Pagani F., Bettini A., Bonomi L., Rinaldi S., Berardi R., Filetti M., Giusti R., Pilotto S., Milella M., Intagliata S., Baggi A., Cortellini A., Soto Parra H., Brighenti M., Petrelli F., Bennati C., Bidoli P., Garassino M. C., and Berruti A.

Abstract

Objectives: The prevalence of Skeletal Related Adverse Events (SREs) in EGFR mutated non-small cell lung cancer (NSCLC) patients with bone metastases, treated with modern tyrosine kinase inhibitors (TKIs), has been scarcely investigated. Materials and Methods: We retrospectively evaluated the data of EGFR mutated NSCLC patients with bone metastases treated with TKIs in 12 Italian centers from 2014 to 2019, with the primary aim to explore type and frequency of SREs. Results: Seventy-seven out of 274 patients enrolled (28%) developed at least one major SRE: 55/274 (20%) bone fractures, 30/274 (11%) spinal cord compression, 5/274 (2%) hypercalcemia. Median time to the onset of SRE was 3.63 months. Nine patients (3%) underwent bone surgery and 150 (55%) radiation therapy on bone. SREs were more frequently observed within the 12 months from TKI start than afterwards (71 vs 29%, p 0.000). Patient Performance Status and liver metastases where independently associated with the risk of developing SREs. Median TKI exposure and overall survival were 11 and 28 months, respectively. Bone resorption inhibitors were associated with a lower risk of death (HR 0.722, 95% CI: 0.504–1.033, p = 0.075) although not statistically significant at multivariate analysis. Conclusion: Bone metastatic NSCLC patients with EGFR mutated disease, treated with EGFR TKIs, have a relatively long survival expectancy and are at high risk to develop SREs. The early SRE occurrence after the TKI start provides the rationale to administer bone resorption inhibitors.

Published
2020

29. Processing of the SIRGAS 2000 GPS Network at DGFI

Author

Kaniuth, K., Tremel, H., Drewes, H., Stuber, K., Maturana, R., Parra, H., Sansò, Fernando, editor, Drewes, Hermann, editor, Dodson, Alan H., editor, Fortes, Luiz Paulo Souto, editor, Sánchez, Laura, editor, and Sandoval, Pedro, editor

Published
2002
Full Text
View/download PDF

30. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Author

Shaw, A. T., Bauer, T. M., De Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D. -W., Mok, T., Polli, A., Thurm, H., Calella, A. M., Peltz, G., Solomon, B. J., and Soto Parra, H.

Subjects
Male, Alectinib, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung/drug therapy, medicine.medical_treatment, 030204 cardiovascular system & hematology, Macrocyclic, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, 030212 general & internal medicine, Non-Small-Cell Lung, Manchester Cancer Research Centre, General Medicine, Middle Aged, Crizotinib/adverse effects, Intention to Treat Analysis, Female, Hyperlipidemias/chemically induced, medicine.drug, Adult, Lactams, Macrocyclic/adverse effects, Lactams, Lactams, Macrocyclic, Anaplastic Lymphoma Kinase/antagonists & inhibitors, Antineoplastic Agents, Hyperlipidemias, 03 medical and health sciences, Crizotinib, ROS1, medicine, Humans, Lung Neoplasms/drug therapy, Lung cancer, Aged, Chemotherapy, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Carcinoma, Cancer, Antineoplastic Agents/adverse effects, medicine.disease, Survival Analysis, Lorlatinib, Mutation, Cancer research, business
Abstract

BACKGROUND: Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non-small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-positive NSCLC is unclear. METHODS: We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced ALK-positive NSCLC who had received no previous systemic treatment for metastatic disease. The primary end point was progression-free survival as assessed by blinded independent central review. Secondary end points included independently assessed objective response and intracranial response. An interim analysis of efficacy was planned after approximately 133 of 177 (75%) expected events of disease progression or death had occurred. RESULTS: The percentage of patients who were alive without disease progression at 12 months was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.19 to 0.41; PCONCLUSIONS: In an interim analysis of results among patients with previously untreated advanced ALK-positive NSCLC, those who received lorlatinib had significantly longer progression-free survival and a higher frequency of intracranial response than those who received crizotinib. The incidence of grade 3 or 4 adverse events was higher with lorlatinib than with crizotinib because of the frequent occurrence of altered lipid levels. (Funded by Pfizer; CROWN ClinicalTrials.gov number, NCT03052608.).

Published
2020

31. The 2010 M w 8.8 Maule Megathrust Earthquake of Central Chile, Monitored by GPS

Author

Vigny, C., Socquet, A., Peyrat, S., Ruegg, J.-C., Métois, M., Madariaga, R., Morvan, S., Lancieri, M., Lacassin, R., Campos, J., Carrizo, D., Bejar-Pizarro, M., Barrientos, S., Armijo, R., Aranda, C., Valderas-Bermejo, M.-C., Ortega, I., Bondoux, F., Baize, S., Lyon-Caen, H., Pavez, A., Vilotte, J. P., Bevis, M., Brooks, B., Smalley, R., Parra, H., Baez, J.-C., Blanco, M., Cimbaro, S., and Kendrick, E.

Published
2011
Full Text
View/download PDF

32. Efecto del cambio del paisaje en la estructura de la comunidad de abejas sin aguijón (Hymenoptera: Apidae) en Meta, Colombia

Author

Guiomar Nates-Parra, Eliana Palacios, and Alejandro Parra-H

Subjects
Abejas sin aguijón, agro-ecosistemas, Colombia, distribución espacial, diversidad, Meliponini, Piedemonte llanero, Agro-ecosystems, conservation, diversity, llanos piedmont, spatial distribution, stingless bees, Biology (General), QH301-705.5
Abstract

Las abejas sin aguijón son unos de los polinizadores naturales más diversos de la fauna Apoidea en los trópicos. Nidifican en diversos sustratos y distintos ambientes, existiendo algunas especies típicas de lugares naturales o artificiales. La alteración del medio donde nidifican tiene un importante impacto sobre la composición natural de su estructura, hecho que se ve reflejado también en la densidad de nidos. Analizamos la composición de la estructura de la comunidad de abejas sin aguijón en tres paisajes del piedemonte llanero colombiano, una región importante por representar la transición entre ambientes andinos y de sabana (seriamente amenazada por la ganadería intensiva). Realizamos muestreos sistemáticos en bosque secundario, agro-ecosistema y zona urbana; registramos la presencia de 204 nidos de 11 géneros representados por 24 especies. La riqueza de abejas sin aguijón fue similar, aun cuando hubo diferencias significativas en la estructura de la comunidad en los tres paisajes. La densidad de nidos por paisaje fue heterogénea y nunca mayor de 16 nidos/Ha. Observamos dos patrones de nidificación y registramos diferente número de especies en la misma zona utilizando otro criterio de muestreo.Effect of landscape change on the structure of the sting-less bee community (Hymenoptera: Apidae) in Meta, Colombia. Stingless bees represent one of the most diversified components of the natural Apoidea fauna of pollinators in the tropics. They use diverse kinds of substrates and inhabit varied habitats. Some species are typical for some natural either artificial place. The landscape alteration were this group of bees nests, has and important impact on the natural composition of its community structure, fact which is reflected in the nest density. We analyzed the structure composition of the stingless bees’ community in three environments in the Colombian llanos piedmont, an important region that represents the transition between Andean ecosystems and a savannah that is seriously threatened by cattle practices. We made systematic samples in secondary forest, agro-ecosystems and urban areas, recording the presence of 204 nests from 11 genera (24 species). The nest density per landscape was heterogeneous and never higher than 16 nests/Ha. We observed two nesting patterns and an effect of sampling criterion on the measured biodiversity. Rev. Biol. Trop. 56 (3): 1295-1308. Epub 2008 September 30.

Published
2008

33. Variación de la comunidad de abejas de las orquídeas (Hymenoptera: Apidae) en tres ambientes perturbados del piedemonte llanero colombiano

Author

Alejandro Parra-H and Guiomar Nates-Parra

Subjects
comunidades, conservación, diversidad, euglosinos, piedemonte llanero colombiano, Colombian eastern llanos piedmont, communities, conservation, diversity, euglossine bees, Biology (General), QH301-705.5
Abstract

Las abejas de las orquídeas subsisten en vastas áreas de bosque tropicales gracias a que mantienen estrechas relaciones con tipos de vegetación particular en diversos micro-hábitats. Con base en este tipo de relaciones con el medio y características biológicas como preferencia por ciertos tipos de néctares y de polen, y diversidad morfológica y etológica de la tribu, es posible evaluar la calidad de un hábitat según la distribución de euglosinos. Este trabajo propone el uso de esta información, además de índices de diversidad para la evaluación de la calidad del medio. Entre marzo y diciembre de 2003 muestreamos tres tipos de paisaje (Urbano, Rural y Conservado) en el piedemonte llanero colombiano, usando redes entomológicas y sustancias aromáticas (Cineol y Metil Salicilato). Para las 15 localidades muestreadas se registraron 17 de las 26 especies conocidas para el área. Eulaema nigrita fue la más frecuente mientras que Euglossa magnipes, E. cybelia, E. heterosticta, E. singularis, Eulaema bombiformis, E. speciosa y Exaerete frontalis correspondieron a ambientes considerados de aceptable a buena calidad. La composición y cercanía de fragmentos de bosque son factores favorables. La diversidad relativa (máxima variación de formas y tamaños dentro de la tribu), sería proporcional a la calidad del medio.Variation of the orchid bees community (Hymenoptera: Apidae) in three altered habitats of the Colombian "llano" piedmont. Orchid bees subsist in vast tropical forest areas because they maintain close relationships with particular plant species in diverse micro-habitats. Based on the relationships among the environment and biological features (food preference, morphologic and ethologic diversity), it is possible to determine habitat quality using the euglossine array. This work proposes the use of this ecological information, in addition to diversity indices, for the evaluation of environmental quality. Fifteen localities in three landscape types (urban, rural and conserved) were sampled in the eastern llanos foothill (Meta, Colombia), between March and December of 2003 using entomological nets, and Cineol and Metil Salicylate as baits. Of the 26 species known to occur in the area, 17 were registered. Eulaema nigrita was the most frequent, while E. speciosa E. bombiformis, Euglossa magnipes, E. cybelia, E. heterosticta, E. singularis and Exaerete frontalis were mostly found in habitats rated "good to acceptable". The vegetation composition and proximity of forest fragments seem to favor some species in disturbed habitats. Relative diversity of bee body shapes and sizes is proportional to habitat quality. Rev. Biol. Trop. 55 (3-4): 931-941. Epub 2007 December, 28.

Published
2007

34. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Author

Landi, L, D'Inca, F, Gelibter, A, Chiari, R, Grossi, F, Delmonte, A, Passaro, A, Signorelli, D, Gelsomino, F, Galetta, D, Giannarelli, D, Soto Parra, H, Minuti, G, Tiseo, M, Migliorino, M, Cognetti, F, Toschi, L, Bidoli, P, Piantedosi, F, Calabro', L, Cappuzzo, F, Landi L., D'Inca F., Gelibter A., Chiari R., Grossi F., Delmonte A., Passaro A., Signorelli D., Gelsomino F., Galetta D., Giannarelli D., Soto Parra H., Minuti G., Tiseo M., Migliorino M. R., Cognetti F., Toschi L., Bidoli P., Piantedosi F., Calabro' L., Cappuzzo F., Landi, L, D'Inca, F, Gelibter, A, Chiari, R, Grossi, F, Delmonte, A, Passaro, A, Signorelli, D, Gelsomino, F, Galetta, D, Giannarelli, D, Soto Parra, H, Minuti, G, Tiseo, M, Migliorino, M, Cognetti, F, Toschi, L, Bidoli, P, Piantedosi, F, Calabro', L, Cappuzzo, F, Landi L., D'Inca F., Gelibter A., Chiari R., Grossi F., Delmonte A., Passaro A., Signorelli D., Gelsomino F., Galetta D., Giannarelli D., Soto Parra H., Minuti G., Tiseo M., Migliorino M. R., Cognetti F., Toschi L., Bidoli P., Piantedosi F., Calabro' L., and Cappuzzo F.

Abstract

Background: Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. Methods: Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. Results: Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p < 0.0001; Cohort B: 13% versus 22%, p = 0.04), shorter progression free survival (PFS; Cohort A: 3.0 versus 4.0 months, p < 0.0001; Cohort B: 2.7 versus 5.2 months, p < 0.0001) and overall survival (OS; Cohort A: 7.4 versus 15.3 months, p < 0.0001; Cohort B: 5.0 versus 10.9 months, p < 0.0001). Moreover, BoM negatively affected outcome irrespective of performance status (PS; OS in both cohorts: p < 0.0001) and liver metastases (OS cohort A: p < 0.0001; OS Cohort B: p = 0.48). At multivariate analysis, BoM independently associated with higher risk of death (cohort A: HR 1.50; cohort B: HR 1.78). Conclusions: BoM impairs immunotherapy efficacy. Accurate bone staging should be included in clinical trials with immunotherapy.

Published
2019

36. Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study

Author

Lonardi, S., Nasti, G., Fagnani, D., Gemma, D., Ciuffreda, L., Granetto, C., Lucchesi, S., Ballestrero, A., Biglietto, M., Proserpio, I., Bergamo, F., Proietti, E., Tonini, G., and Soto Parra, H

Subjects
Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Genotype, Bevacizumab, Colorectal cancer, First line, Angiogenesis Inhibitors, Metastatic colorectal cancer, bevacizumab, clinical practice, progression-free survival, therapy interruption, Disease-Free Survival, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Humans, Medicine, Progression-free survival, Neoplasm Metastasis, Aged, business.industry, General Medicine, Middle Aged, medicine.disease, Discontinuation, 030104 developmental biology, Italy, 030220 oncology & carcinogenesis, Mutation, Mutation (genetic algorithm), Female, Observational study, Colorectal Neoplasms, business, medicine.drug
Abstract

Aims: BEAWARE investigated the pattern of first-line bevacizumab early interruption in the Italian real-world setting of metastatic colorectal cancer. Methods: A total of 386 patients were followed for 15 months after first-line chemotherapy + bevacizumab start. The rate of bevacizumab interruption for progression or adverse drug reactions (ADRs) constituted the primary endpoint. Results: A total of 78.2% of patients interrupted bevacizumab: 56.6% for progression, 7.3% for ADRs, and 36.1% for other reasons. Median treatment duration was 6.7, 2.5, and 4.6 months, respectively. Median progression-free survival was 10.3 months; however, 35.8% of patients were not progressed and were thus censored at the data cutoff of 15 months, while 21.8% were still receiving bevacizumab. Patients discontinuing for progression/ADRs more frequently had metastases in >1 site ( p = .0001), and a shorter median progression-free survival (6.9 vs 13.9 months, p < .0001). Conclusions: In Italy, first-line bevacizumab is interrupted mainly for progression, only 7.3% due to adverse events, and about one third of cases for other reasons. In clinical practice, the attitude to treat until progression as per guidelines might be implemented. ClinicalTrials.gov Identifier: NCT01609075

Published
2019

38. Mecanismos patogénicos de infección por SARS-CoV-2 y enfermedad renal: una perspectiva clínico-molecular

Author

Torres,W, Morillo,V, Manzano,A, Suarez,MK, Parra,H, Lameda,V, Nava,M, D'Marco,L, Puchades,MJ, Medina,O, Guerra-Torres,XE, and Bermúdez,V

Subjects
SARS-CoV-2, COVID-19, Enzima convertidora de angiotensina 2, Enfermedad renal crónica, Lesión renal aguda
Abstract

Resumen La infección por SARS-CoV-2 se ha convertido en un problema mundial de salud pública. Su presentación clínica es variada, desde benigna hasta un síndrome de distrés respiratorio agudo, afectación sistémica y fallo multiorgánico. La severidad del cuadro clínico depende de factores biológicos del virus y del huésped y de comorbilidades como la enfermedad renal. Además, la interacción entre el virus, la enzima convertidora de angiotensina 2 y la respuesta inmunológica exacerbada podría conducir al desarrollo de lesión renal aguda. Sin embargo, las implicaciones de la infección por SARS-CoV-2 sobre las células renales, las repercusiones pronósticas en los pacientes con enfermedad renal crónica y su efecto a largo plazo sobre la función renal no están del todo claras. El objetivo es revisar el papel del SARS-CoV-2 en la enfermedad renal aguda y crónica, y sus posibles mecanismos patogénicos en la afectación renal.

Published
2021

39. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients

Author

Malapelle, U, Passiglia, F, Cremolini, C, Reale, M, Pepe, F, Pisapia, P, Avallone, A, Cortinovis, D, De Stefano, A, Fassan, M, Fontanini, G, Galetta, D, Lauricella, C, Listì, A, Loupakis, F, Pagni, F, Pietrantonio, F, Pilotto, S, Righi, L, Bianchi, A, Parra, H, Tiseo, M, Verzè, M, Troncone, G, Novello, S, Malapelle, Umberto, Passiglia, Francesco, Cremolini, Chiara, Reale, Maria Lucia, Pepe, Francesco, Pisapia, Pasquale, Avallone, Antonio, Cortinovis, Diego, De Stefano, Alfonso, Fassan, Matteo, Fontanini, Gabriella, Galetta, Domenico, Lauricella, Calogero, Listì, Angela, Loupakis, Fotios, Pagni, Fabio, Pietrantonio, Filippo, Pilotto, Sara, Righi, Luisella, Bianchi, Andrea Sartore, Parra, Hector Soto, Tiseo, Marcello, Verzè, Michela, Troncone, Giancarlo, Novello, Silvia, Malapelle, U, Passiglia, F, Cremolini, C, Reale, M, Pepe, F, Pisapia, P, Avallone, A, Cortinovis, D, De Stefano, A, Fassan, M, Fontanini, G, Galetta, D, Lauricella, C, Listì, A, Loupakis, F, Pagni, F, Pietrantonio, F, Pilotto, S, Righi, L, Bianchi, A, Parra, H, Tiseo, M, Verzè, M, Troncone, G, Novello, S, Malapelle, Umberto, Passiglia, Francesco, Cremolini, Chiara, Reale, Maria Lucia, Pepe, Francesco, Pisapia, Pasquale, Avallone, Antonio, Cortinovis, Diego, De Stefano, Alfonso, Fassan, Matteo, Fontanini, Gabriella, Galetta, Domenico, Lauricella, Calogero, Listì, Angela, Loupakis, Fotios, Pagni, Fabio, Pietrantonio, Filippo, Pilotto, Sara, Righi, Luisella, Bianchi, Andrea Sartore, Parra, Hector Soto, Tiseo, Marcello, Verzè, Michela, Troncone, Giancarlo, and Novello, Silvia

Abstract

Rat sarcoma (RAS) oncogenes have intensively been investigated during the last decades. Taking into account all human tumours, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene is the most frequently mutated (about 22%) among the three isoforms, followed by Neuroblastoma RAS Viral Oncogene Homolog (NRAS) (8%) and Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) (3%). In the last years, careful attention has been paid on KRAS and NRAS gene mutations in non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC) patients because of their prognostic and predictive roles. In particular, a large body of literature data has been generated investigating clinical outcomes of targeted treatments in NSCLC and CRC KRAS- and NRAS-mutated patients. The latest evidences are here reviewed, providing also an overview of the real-world RAS mutation testing practice across different Italian laboratories. On this basis, we propose a knowledge-based system, www.rasatlas.com, to support the healthcare personnel in the management of patients featuring RAS gene mutations in the landscape of precision oncology.

Published
2021

41. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Bajetta, E., Floriani, I., Di Bartolomeo, M., Labianca, R., Falcone, A., Di Costanzo, F., Comella, G., Amadori, D., Pinto, C., Carlomagno, C., Nitti, D., Daniele, B., Mini, E., Poli, D., Santoro, A., Mosconi, S., Casaretti, R., Boni, C., Pinotti, G., Bidoli, P., Landi, L., Rosati, G., Ravaioli, A., Cantore, M., Di Fabio, F., Aitini, E., Marchet, A., Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Poli, D., Mangano, S., Tonato, M., Zucca, E., Valsecchi, MG., Floriani, I., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Bajetta, E., Di Bartolomeo, M., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., DellʼOro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Labianca, R., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Amadori, D., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Falcone, A., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Di Costanzo, F., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Pinto, C., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Daniele, B., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Nitti, D., Marchet, A., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., and Otero, M.

Published
2014
Full Text
View/download PDF

42. 97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

Author

Robinson, A.G., primary, Vicente, D., additional, Tafreshi, A., additional, Parra, H. Soto, additional, Mazieres, J., additional, Cicin, I., additional, Medgyasszay, B., additional, Rodríguez-Cid, J., additional, Okamoto, I., additional, Lee, S., additional, Ramlau, R., additional, Vladimirov, V., additional, Cheng, Y., additional, Halmos, B., additional, Liu, C-C., additional, Schwarzenberger, P., additional, Piperdi, B., additional, and Paz-Ares, L., additional

Published
2021
Full Text
View/download PDF

43. P35.14 NGS-Based Molecular Profiling of ‘Quadruple-Negative’ (EGFR/KRAS/ALK/ROS1) Advanced Non-Small-Cell Lung Cancer (aNSCLC).

Author

Pilotto, S., primary, Sperduti, I., additional, Sposito, M., additional, Casali, M., additional, Ferrara, M.G., additional, Calvetti, L., additional, Veccia, A., additional, Bonato, A., additional, Sartori, G., additional, Belluomini, L., additional, Vita, E., additional, Cucciniello, L., additional, Inzerilli, N., additional, Parra, H. Soto, additional, Aprile, G., additional, Caffo, O., additional, Scarpa, A., additional, Tortora, G., additional, Bria, E., additional, and Milella, M., additional

Published
2021
Full Text
View/download PDF

46. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial

Author

Di Bartolomeo, M., Morano, F., Raimondi, A., Miceli, R., Corallo, S., Tamborini, E., Perrone, F., Antista, M., Niger, M., Pellegrinelli, A., Randon, G., Pagani, F., Martinetti, A., Fuca, G., Pietrantonio, F., and Soto Parra, H.

Subjects
0301 basic medicine, Oncology, PD-L1, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Docetaxel, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Stomach Neoplasms, Internal medicine, Post-hoc analysis, Gastrointestinal Cancer, Antineoplastic Combined Chemotherapy Protocols, medicine, Tumor Microenvironment, Humans, Chemotherapy, Adjuvant, business.industry, Microsatellite instability, Cancer, medicine.disease, Prognosis, Adjuvant chemotherapy, Regimen, 030104 developmental biology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, FOLFIRI, Biomarker (medicine), Fluorouracil, Cisplatin, business, Gastric cancer, Biomarkers, medicine.drug
Abstract

BACKGROUND: Patients with high microsatellite instability (MSI) gastric cancer (GC) show improved survival and no benefit or harm from adjuvant and/or perioperative chemotherapy. The role of immune microenvironment in GC is largely unknown. MATERIALS AND METHODS: In the present study, 256 tumor tissue blocks were centrally collected from patients enrolled in ITACA‐S, a randomized adjuvant trial of 5‐FU/LV versus sequential FOLFIRI and cisplatin‐docetaxel. MSI status was assessed by multiplex PCR, inflammatory reaction by H&E morphological assessment, and programmed death‐ligand 1 (PD‐L1) expression by immunohistochemistry. RESULTS: Overall, 9% patients had MSI‐high tumors, 23% had high inflammatory reaction, 11% had tumor PD‐L1 ≥ 1%, and 11% had stromal PD‐L1 ≥ 1%. A significant association with disease‐free survival (DFS) and overall survival (OS) was found for MSI‐high (hazard ratio [HR], 0.43; p = .02; HR, 0.40; p = .02) and high inflammatory reaction (HR, 0.55; p = .010; HR, 0.53; p = .008) but not for PD‐L1. At multivariable analysis, only MSI showed an independent association with both DFS (p = .02) and OS (p = .01), whereas inflammatory reaction showed an independent association only with OS (p = .04). Patients with tumor PD‐L1 ≥ 1% had a significantly longer DFS in sequential chemotherapy than in than 5‐FU/LV arm (interaction p = .04) and a trend for OS (interaction p = .12). CONCLUSION: Our data suggest that MSI status could be a useful prognostic biomarker in patients with radically resected stage II–III GC and should be used as stratification factor in future trials. Tumor PD‐L1 ≥ 1% should be further investigated as a potential predictor of benefit from intensive chemotherapy. IMPLICATIONS FOR PRACTICE: In this post hoc analysis of patients with radically resected gastric cancer randomized to an intensive sequential chemotherapy regimen versus 5‐FU/LV monotherapy as adjuvant treatment in the ITACA‐S trial, MSI‐high status was independently associated with better disease‐free survival and overall survival (OS) and inflammatory reaction was independently associated with better OS. Moreover, tumor PD‐L1 expression ≥1% was associated with greater benefit from intensive sequential chemotherapy compared with 5‐fluorouracil plus leucovorin (5‐FU/LV), whereas PD‐L1 expression

Published
2020

48. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Author

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodriguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., Finley, G., Kelsch, C., Lee, A., Coleman, S., Deng, Y., Shen, Y., Kowanetz, M., Lopez-Chave, A., Sandler, A., Reck, M., Soto Parra, H, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, and MUMC+: MA Med Staf Spec Longziekten (9)

Subjects
0301 basic medicine, Oncology, Male, Vascular Endothelial Growth Factor A, Lung Neoplasms, MULTICENTER, THERAPY, B7-H1 Antigen, Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Medicine, Anaplastic Lymphoma Kinase, Neoplasm Metastasis, Non-Small-Cell Lung, DOCETAXEL, education.field_of_study, Aged, Antibodies, Monoclonal, Bevacizumab, Carcinoma, Non-Small-Cell Lung, Female, Genes, erbB-1, Humans, Middle Aged, Mutation, Paclitaxel, Receptor Protein-Tyrosine Kinases, Survival Analysis, Immunotherapy, Hazard ratio, PHASE-III TRIAL, General Medicine, CHEMOTHERAPY, OPEN-LABEL, CANCER, Docetaxel, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Population, BEVACIZUMAB, Antibodies, 03 medical and health sciences, Atezolizumab, Internal medicine, Lung cancer, education, Survival analysis, erbB-1, business.industry, Carcinoma, medicine.disease, 030104 developmental biology, chemistry, Genes, ANTIBODY, CELLS, business
Abstract

Background The cancer-cell–killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor–mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non–small-cell lung cancer (NSCLC) who had not previously received chemotherapy. Methods We randomly assigned patients to receive atezolizumab plus carboplatin plus paclitaxel (ACP), bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP (ABCP) every 3 weeks for four or six cycles, followed by maintenance therapy with atezolizumab, bevacizumab, or both. The two primary end points were investigator-assessed progression-free survival both among patients in the intention-to-treat population who had a wild-type genotype (WT population; patients with EGFR or ALK genetic alterations were excluded) and among patients in the WT population who had high expression of an effector T-cell (Teff) gene signature in the tumor (Teff-high WT population) and overall survival in the WT population. The ABCP group was compared with the BCP group before the ACP group was compared with the BCP group. Results In the WT population, 356 patients were assigned to the ABCP group, and 336 to the BCP group. The median progression-free survival was longer in the ABCP group than in the BCP group (8.3 months vs. 6.8 months; hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.52 to 0.74; P

Published
2018

50. PIN41 Cost Minimization and Opportunity Cost Analysis of FULLY-Liquid Vaccines Versus NON-FULLY Liquid Vaccines That Need Reconstitution, for Hexavalent and Menawyc Vaccines in Spain

Author

Cuesta, I., primary, Carcedo, D., additional, Del Mar Menor, M.J., additional, Drago Manchón, G., additional, Escolano, M., additional, López-Belmonte, J.L., additional, López, S., additional, Parra, H., additional, Rivero Cuadrado, A., additional, and Tamames Gómez, S., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results